MaxCyte, Inc., a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, ...
The study, published today in JAMA Network Open, tracked patients hospitalized for hip fractures in Victoria, Australia from March 2013 through June 2018, who had used gabapentinoids before the injury ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback